321 related articles for article (PubMed ID: 31156798)
1. Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia.
González-Porras JR; Godeau B; Carpenedo M
Ther Adv Hematol; 2019; 10():2040620719837906. PubMed ID: 31156798
[TBL] [Abstract][Full Text] [Related]
2. Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study.
Cai X; Fu H; Zhao X; Lu J; Jiang Q; Chang Y; Huang X; Zhang X
Chin Med J (Engl); 2022 Oct; 135(19):2344-2350. PubMed ID: 36535011
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M
Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
[TBL] [Abstract][Full Text] [Related]
4. Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP).
Kapur R; Aslam R; Speck ER; Rebetz JM; Semple JW
Platelets; 2020; 31(3):399-402. PubMed ID: 31146647
[TBL] [Abstract][Full Text] [Related]
5. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
6. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
Lakhwani S; Perera M; Fernández-Fuertes F; Ríos de Paz MA; Torres M; Raya JM; Hernández MT
Eur J Haematol; 2017 Oct; 99(4):372-377. PubMed ID: 28759125
[TBL] [Abstract][Full Text] [Related]
7. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
[TBL] [Abstract][Full Text] [Related]
8. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
Al-Samkari H; Kuter DJ
Am J Hematol; 2018 Dec; 93(12):1501-1508. PubMed ID: 30187942
[TBL] [Abstract][Full Text] [Related]
9. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Kühne T; Imbach P
Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
[TBL] [Abstract][Full Text] [Related]
10. Romiplostim as a treatment for immune thrombocytopenia: a review.
Chalmers S; Tarantino MD
J Blood Med; 2015; 6():37-44. PubMed ID: 25632241
[TBL] [Abstract][Full Text] [Related]
11. Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia.
Garzon AM; Mitchell WB
Front Pediatr; 2015; 3():70. PubMed ID: 26322297
[TBL] [Abstract][Full Text] [Related]
12. The role of romiplostim for pediatric patients with immune thrombocytopenia.
Al-Samkari H; Grace RF; Kuter DJ
Ther Adv Hematol; 2020; 11():2040620720912992. PubMed ID: 32523658
[TBL] [Abstract][Full Text] [Related]
13. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers.
Cantoni S; Carpenedo M; Mazzucconi MG; De Stefano V; Carrai V; Ruggeri M; Specchia G; Vianelli N; Pane F; Consoli U; Artoni A; Zaja F; D'adda M; Visentin A; Ferrara F; Barcellini W; Caramazza D; Baldacci E; Rossi E; Ricco A; Ciminello A; Rodeghiero F; Nichelatti M; Cairoli R
Am J Hematol; 2018 Jan; 93(1):58-64. PubMed ID: 28983953
[TBL] [Abstract][Full Text] [Related]
14. Comparative Utilization and Efficacy of Thrombopoietin Receptor Agonists in Relapsed/Refractory Immune Thrombocytopenia.
Arnall JR; DiSogra KY; Downing L; Elmes JB; Tran T; Moore DC
Am J Ther; 2021 Jan; 28(5):e525-e530. PubMed ID: 33491968
[TBL] [Abstract][Full Text] [Related]
15. Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review.
Birocchi S; Podda GM; Manzoni M; Casazza G; Cattaneo M
Platelets; 2021 Feb; 32(2):216-226. PubMed ID: 32281449
[TBL] [Abstract][Full Text] [Related]
16. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults.
Červinek L; Mayer J; Doubek M
Int J Hematol; 2015 Jul; 102(1):7-11. PubMed ID: 25833724
[TBL] [Abstract][Full Text] [Related]
17. Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations.
Carpenedo M; Baldacci E; Baratè C; Borchiellini A; Buccisano F; Calvaruso G; Chiurazzi F; Fattizzo B; Giuffrida G; Rossi E; Palandri F; Scalzulli PR; Siragusa SM; Vitucci A; Zaja F
Ther Adv Hematol; 2021; 12():20406207211048361. PubMed ID: 34646432
[TBL] [Abstract][Full Text] [Related]
18. Treatment characteristics, efficacy and safety of thrombopoietin analogues in routine management of primary immune thrombocytopenia.
Mingot-Castellano ME; Caparrós IS; Fernández F; Perera-Alvarez MDM; Jimenez-Bárcenas R; Casaus García A; González-Silva M; Yera-Cobo M; Nieto-Hernandez MM; Rodríguez-Fernandez MJ; Díaz-Canales D
Blood Coagul Fibrinolysis; 2018 Jun; 29(4):374-380. PubMed ID: 29738335
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review.
Agarwal N; Mangla A
Ther Adv Hematol; 2021; 12():20406207211001139. PubMed ID: 33796239
[TBL] [Abstract][Full Text] [Related]
20. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
Kuter DJ
Blood Rev; 2022 May; 53():100909. PubMed ID: 34815110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
